Cancer immunotherapy that genetically engineers viruses to turn cancer cells into biofactories for their own destruction.
Kopra Bio develops genetically engineered virus-based cancer immunotherapies that reprogram tumor cells to produce agents of their own destruction. The company's lead program targets glioblastoma, the most aggressive form of brain cancer, using technology developed at UCSF. In preclinical models, Kopra Bio's treatment improved survival from 0% with the current FDA-approved standard of care to 90%. The company is pursuing a next-generation immunotherapy with a market opportunity analogous to Keytruda, the $25B/year cancer drug. Kopra Bio is a product of Kopra Bio.